Europska Unija - hrvatski - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastična sredstva - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastična sredstva - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).

Europska Unija - hrvatski - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - leukemije, dlakave stanice - antineoplastična sredstva - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

Europska Unija - hrvatski - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - antineoplastična sredstva - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

Europska Unija - hrvatski - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - karcinom, ne-malih stanica pluća - antineoplastična sredstva - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb - caspofunginum - prašak za koncentrat za otopinu za infuziju - 5,2 mg/ml - urbroj: jedna bočica sadrži 50 mg kaspofungina (u obliku kaspofunginacetata); nakon rekonstitucije svaki ml koncentrata sadrži 5,2 mg kaspofungina

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb - caspofunginum - prašak za koncentrat za otopinu za infuziju - 7,2 mg/ml - urbroj: jedna bočica sadrži 70 mg kaspofungina (u obliku kaspofunginacetata); nakon rekonstitucije svaki ml koncentrata sadrži 7,2 mg kaspofungina

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

xellia pharmaceuticals aps, dalslandsgade 11, kopenhagen s, danska - caspofunginum - prašak za koncentrat za otopinu za infuziju - 50 mg - urbroj: svaka bočica sadrži 50 mg kaspofungina (u obliku acetata)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

xellia pharmaceuticals aps, dalslandsgade 11, kopenhagen s, danska - caspofunginum - prašak za koncentrat za otopinu za infuziju - 70 mg - urbroj: svaka bočica sadrži 70 mg kaspofungina (u obliku acetata)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

sandoz d.o.o., maksimirska 120, zagreb - caspofunginum - prašak za koncentrat za otopinu za infuziju - 50 mg - urbroj: svaka bočica sadrži 50 mg kaspofungina (u obliku acetata); koncentracija rekonstituirane otopine u bočici je 5,2 mg/ml